Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
UNIVERSITY OF ZURICH has 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 3 matters are assigned to 3 distinct examiners and 3 distinct art units. This one-to-one ratio between the 3 pending office actions and the 3 distinct examiners suggests that each application is being evaluated by a different technical specialist. The prosecution effort is decentralized across 3 separate USPTO divisions.
SHIAO, REI TSANG is the busiest examiner for the portfolio, managing 1 pending office action. With 3 distinct examiners each responsible for 1 matter, the workload is decentralized. The university must navigate the specific standards and timelines of 3 separate art units to advance its current pending applications. Practitioners should prepare for distinct prosecution paths as each of the 3 pending office actions is subject to the review of a different examiner.
The lack of concentration across the 3 distinct art units reduces the risk that a single adverse trend will affect the entire portfolio. However, it also requires the university to be responsive to the diverse feedback from 3 different examiners. Success in the Biotechnology & Pharmaceuticals sector for this university depends on effectively navigating the unique requirements of each of the 3 pending office actions and the specific preferences of SHIAO, REI TSANG.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| §112 only | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHIAO, REI TSANG | 1 | 79.9% | -33.5% |
| NICKOL, GARY B | 1 | 46.6% | +33.3% |
| TAYLOR, LIA ELAN | 1 | 64.2% | +29.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18506287 | N6-ADENOSINE-METHYLTRANSFERASE INHIBITORS IN CANCER TREATMENT | SHIAO, REI TSANG | — |
| 18549629 | ANTIBODIES AGAINST TDP-43 AND METHODS OF USING THE SAME | NICKOL, GARY B | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18256817 | HDAC6 BINDING PROTEINS AND THEIR ANTI-VIRAL USE | TAYLOR, LIA ELAN | 55d |
| 18549629 | ANTIBODIES AGAINST TDP-43 AND METHODS OF USING THE SAME | NICKOL, GARY B | — |
| Art Unit | Apps |
|---|---|
| 1691 | 1 |
| 1643 | 1 |
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18506287 | N6-ADENOSINE-METHYLTRANSFERASE INHIBITORS IN CANCER TREATMENT | SHIAO, REI TSANG | 1691 | §102§103 | Non-Final OA | — | Pending | Nov 10, 2023 |
| 18549629 | ANTIBODIES AGAINST TDP-43 AND METHODS OF USING THE SAME | NICKOL, GARY B | 1643 | §101§112 | Non-Final OA | — | Pending | Sep 08, 2023 |
| 18256817 | HDAC6 BINDING PROTEINS AND THEIR ANTI-VIRAL USE | TAYLOR, LIA ELAN | 1641 | §112 | Final Rejection | 55d | Pending | Jun 09, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUNIVERSITY OF ZURICH has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Rei Tsang Shiao has the most, with 1 of UNIVERSITY OF ZURICH's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
